| Name | Title | Contact Details |
|---|
Dharmacon Research is a Lafayette, CO-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
PharmaForm is a leading specialty contract development and manufacturing organization focusing on oral and transmucosal dosage forms. Founded in 1996, PharmaForm has built a reputation for delivering novel and innovative solutions to challenging problems
We operate with a “No Analog” mindset—continually pushing boundaries, navigating new terrain and unleashing fresh thinking. We are committed to seeking better outcomes which compels us to ask questions that have not been asked before or remain unresolved. We are driven by a desire to create meaningful impact across business, health and society to ease the burden on people living with chronic diseases. Intarcia is a rapidly emerging biotech company dedicated to redesigning the treatment, prevention and experience of chronic disease. Our cross-disciplinary teams include forward-thinking scientists and entrepreneurs collaborating in a fast-paced environment redefining the future of medicine.
Diassess Inc. is revolutionizing the way infectious diseases are prevented, diagnosed, and monitored by developing the tools necessary to empower people to become knowledgeable about their health.
Spotlight Therapeutics is a venture funded early-stage biotechnology company with a mission to develop a new class of therapeutics by enabling direct in vivo gene editing. Founded by Alex Marson (UCSF), Jacob Corn (UC Berkeley), and Patrick Hsu (Salk Institute) in December of 2017, Spotlight is building its core technology platform to achieve precise in vivo gene editing in targeted cell populations. With a therapeutic focus centered on oncology, our engineered nucleases edit the genes in targeted disease organs thereby inactivating or altering the gene product. We are hiring rapidly to build out our cutting-edge research and development team. This team is responsible for preclinical development ranging from protein engineering, gene editing to immuno-oncology and in vivo safety studies. Join us and work on the next generation of gene editing therapeutics in a fast-paced and exciting environment.